Two-year results from a phase 2 extension study of oral amiselimod in relapsing multiple sclerosis.

Kappos L, Arnold DL, Bar-Or A, Camm AJ, Derfuss T, Sprenger T, Davies M, Piotrowska A, Ni P, Harada T.

DOI: 10.1177/1352458517728343
Published: 2017-09-15
Container: Mult Scler
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1177/1352458517728343,
  title = {Two-year results from a phase 2 extension study of oral amiselimod in relapsing multiple sclerosis.},
  author = {Kappos L and  Arnold DL and  Bar-Or A and  Camm AJ and  Derfuss T and  Sprenger T and  Davies M and  Piotrowska A and  Ni P and  Harada T.},
  year = {2018},
  journal = {Mult Scler},
  doi = {10.1177/1352458517728343},
  url = {https://doi.org/10.1177/1352458517728343}
}

RIS

TY  - JOUR
TI  - Two-year results from a phase 2 extension study of oral amiselimod in relapsing multiple sclerosis.
AU  - Kappos L
AU  -  Arnold DL
AU  -  Bar-Or A
AU  -  Camm AJ
AU  -  Derfuss T
AU  -  Sprenger T
AU  -  Davies M
AU  -  Piotrowska A
AU  -  Ni P
AU  -  Harada T.
PY  - 2018
JO  - Mult Scler
DO  - 10.1177/1352458517728343
UR  - https://doi.org/10.1177/1352458517728343
ER  -

APA

L, K., DL, A., A, B., AJ, C., T, D., T, S., M, D., A, P., P, N., & T., H. (2018). Two-year results from a phase 2 extension study of oral amiselimod in relapsing multiple sclerosis.. Mult Scler. https://doi.org/10.1177/1352458517728343

Source records

europe-pmc · retrieved 2026-09-25T01:08:08.127Z